Skip to search formSkip to main contentSkip to account menu

Dihydroorotate Dehydrogenase Inhibitor

Known as: Dihydroorotate Dehydrogenase Inhibitors 
Any substance that inhibits dihydroorotate reductase, an enzyme required for de novo biosynthesis of pyrimidine. Inhibition of dihydroorotate… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model
The malaria parasite Plasmodium falciparum readily develops resistance to dihydroorotate dehydrogenase inhibitors in vitro and in… 
2018
2018
Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor
Abstract DUP-785 (Brequinar sodium) is a potent inhibitor of the mitochondrial dihydroorotate dehydrogenase (DHO-DH), a rate… 
Highly Cited
2018
Highly Cited
2018
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a…
2013
2013
The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors
Dihydroorotate dehydrogenase (DHODH) is an important drug target due to its prominent role in pyrimidine biosynthesis… 
2012
2012
Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.
This study applied an efficient virtual screening strategy integrating molecular docking with MM-GBSA rescoring to identify… 
2012
2012
3D-QSAR studies of triazolopyrimidine derivatives of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors using a combination of molecular dynamics, docking, and genetic algorithm-based…
A series of 35 triazolopyrimidine analogues reported as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors… 
Highly Cited
2010
Highly Cited
2010
Chemometric modeling, docking and in silico design of triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors as antimalarials.
  • P. OjhaK. Roy
  • European journal of medicinal chemistry
  • 2010
  • Corpus ID: 24879544
Highly Cited
2009
Highly Cited
2009
Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.
Plasmodium falciparum causes 1-2 million deaths annually. Yet current drug therapies are compromised by resistance. We previously… 
1998
1998
Dihydroorotate Dehydrogenase Inhibitors: Quantitative Structure-activity Relationship Analysis
AbstractPurpose. The main purpose of this study is to analyze the quantitative structure-activity relationship of two series of… 
Highly Cited
1996
Highly Cited
1996
Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl…
The active metabolite (2) of the novel immunosuppressive agent leflunomide (1) has been shown to inhibit the enzyme… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)